[go: up one dir, main page]

KR960034178A - 벤자제핀- 벤즈옥사제핀- 및 벤조티아제핀-n- 아세트산 유도체와 그 제조방법 및 그들을 함유한 약제학적 조성물 - Google Patents

벤자제핀- 벤즈옥사제핀- 및 벤조티아제핀-n- 아세트산 유도체와 그 제조방법 및 그들을 함유한 약제학적 조성물 Download PDF

Info

Publication number
KR960034178A
KR960034178A KR1019960007794A KR19960007794A KR960034178A KR 960034178 A KR960034178 A KR 960034178A KR 1019960007794 A KR1019960007794 A KR 1019960007794A KR 19960007794 A KR19960007794 A KR 19960007794A KR 960034178 A KR960034178 A KR 960034178A
Authority
KR
South Korea
Prior art keywords
group
hydrogen
vivo
general formula
alkyl
Prior art date
Application number
KR1019960007794A
Other languages
English (en)
Other versions
KR100482499B1 (ko
Inventor
발데크 하랄드
휠트제 다크마르
메싱거 요제프
안텔 요헨
부를 미하일
토르멜렌 딜크
Original Assignee
디터 라우어
칼리-케미 파마 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디터 라우어, 칼리-케미 파마 게엠베하 filed Critical 디터 라우어
Publication of KR960034178A publication Critical patent/KR960034178A/ko
Application granted granted Critical
Publication of KR100482499B1 publication Critical patent/KR100482499B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

NEP-억제효과를 갖는 하기 일반식(Ⅰ)의 화합물 및 생리적으로 내성을 갖는 그의 염.
여기에서 R1은 저급알콕시라디칼이 저급알콕시기로 치환되는 저급 알콕시-저급-알킬기이거나, 페닐고리에서 저급알킬, 저급알콕시 또는 할로겐으로 선택적 치환이 가능한 페닐-저급-알킬기 또는 페닐옥시-저급 알킬기이거나, 또는 나프틸-저급-알킬기이며, A는 CH2, O 또는 S이며, R2는 수소 또는 할로겐이며, R3는 수소 또는 할로겐이며, R4는 수소 또는 생체내 가변성 에스테르를 형성하는 기이고, R5는 수소 또는 생체내 가변성 에스테르를 형성하는 기이다.

Description

벤자제핀- 벤즈옥사제핀- 및 벤조티아제핀-N-아세트산 유도체와 그 제조방법 및 그들을 함유한 약제학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 하기 일반식(Ⅰ)로 표시되는 화합물 및 생리학적으로 내성을 갖는 그의 염
    여기에서 R1은 저급알콕시라디칼이 저급알콕시기로 치환되는 저급 알콕시-저급-알킬기이거나, 페닐고리에서 저급알킬, 저급알콕시 또는 할로겐으로 선택적 치환이 가능한 페닐-저급-알킬기 또는 페닐옥시-저급-알킬기이거나, 또는 나프틸-저급-알킬기이며, A는 CH2, O 또는 S이며, R2는 수소 또는 할로겐이며, R3는 수소 또는 할로겐이며, R4는 수소 또는 생체내 가변성 에스테르를 형성하는 기이고, R5는 수소 또는 생체내 가변성 에스테르를 형성하는 기이다.
  2. 제1항에 있어서, R4및/또는 R5가 생체내 가변성 에스테르를 형성하는 기인 것을 특징으로 하는 화합물.
  3. 상기 전 청구항 중 어느 한 항에서, 생체내 가변성 에스테를 형성하는 기는 저급알킬기, 페닐고리에서 저급알킬기 또는 인접한 두 탄소원자들과 결합한 저급 알킬렌 사슬로 선택적으로 치환되는 페닐 또는 페닐-저급-알킬기 특히, 페닐, 벤질 또는 인도닐, 디옥솔란 고리에서 저급알킬로 선택적으로 치환되는 디옥솔라닐메틸기 특히, (2,2-디메틸-1,3-디옥솔란-4-일)메틸 또는 옥시메틸기상에서 저급알킬로 선택적으로 치환되는 C2-C6-알카노일옥시메틸기인 것을 특징으로 하는 화합물.
  4. 상기 전 청구항 중 어느 한 항에 있어서, R4는 생체내 가변성 에스테르를 형성하는 기이고, R5는 수소인 것을 특징으로 하는 화합물.
  5. 상기 전 청구항 중 어느 한 항에 있어서, A는 CH2인 것을 특징으로 하는 화합물.
  6. 제5항에 있어서, R1은 펜에틸기 또는 나프틸에틸기이고 R2는 수소인 것을 특징으로 하는 화합물.
  7. 약리학적 유효량의 제1항에 따른 화합물 및 통상의 약제학적 보조물질 및/또는 부형제들을 함유하는 약제.
  8. 하기 일반식(Ⅱ)의 산 또는 그의 반응성산유도체와 하기 일반식(Ⅲ)의 아민이 반응하여 하기 일반식(Ⅳ)의 아미드가 생성되며, 하기 일반식(Ⅳ)의 화합물에 있는 산보호기 R4aR5a가 생체내 가변성 에스테르를 형성하는 기가 아니면 이들은 적당한 순서에서 동시에 또는 연속적으로 제거되며, 필요하다면 비보호 산성기는 하기 일반식(Ⅴ)의 알코올 또는 상응하는 하기 일반식(Ⅴ)의 반응성유도체와 에스테르화반응하며, 필요하다면 생성된 하기 일반식(Ⅰ)의 산이 생리학적으로 내성인 그의 염으로 전환되거나 하기 일반식(Ⅰ)의산의 염이 유리 산으로 전환되는 것을 특징으로 하는 하기 일반식(Ⅰ)의 화합물 및 생리학적으로 내성을 갖는 그의 염의 제조방법.
    여기에서 R1은 저급 알콕시 라디칼이 저급알콕시기로 치환되는 저급 알콕시-저급-알킬기이거나, 페닐고리에서 저급알킬, 저급알콕시 또는 할로겐으로 선택적 치환이 가능한 페닐-저급-알킬기 또는 페닐옥시-저급 알킬기이거나, 또는 나프틸-저급-알킬기이며, A는 CH2, O 또는 S이며, R2는 수소 또는 할로겐이며, R3는 수소 또는 할로겐이며, R4는 수소 또는 생체내 가변성 에스테르를 형성하는 기이고, R5는 수소 또는 생체내 가변성 에스테르를 형성하는 기이며,
    여기에서 R1은 상기한 바와 같고 R4a는 산보호기이며,
    여기에서 R2, R3및 A는 상기한 바와 같고 R5a는 산보호기이며,
    여기에서 R1, R2, R3, R4a, R5a및 A는 상기한 바와 같고,
    여기에서 R6은 생체내 가변성 에스테르를 형성하는 기이고 X는 제거될 수 있는 반응성기이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960007794A 1995-03-23 1996-03-21 벤자제핀-,벤즈옥사제핀-및벤조티아제핀-n-아세트산유도체와그제조방법및그들을함유한약제학적조성물 Expired - Fee Related KR100482499B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19510566.4 1995-03-23
DE19510566A DE19510566A1 (de) 1995-03-23 1995-03-23 Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (2)

Publication Number Publication Date
KR960034178A true KR960034178A (ko) 1996-10-22
KR100482499B1 KR100482499B1 (ko) 2006-08-23

Family

ID=7757471

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960007794A Expired - Fee Related KR100482499B1 (ko) 1995-03-23 1996-03-21 벤자제핀-,벤즈옥사제핀-및벤조티아제핀-n-아세트산유도체와그제조방법및그들을함유한약제학적조성물

Country Status (25)

Country Link
US (1) US5677297A (ko)
EP (1) EP0733642B1 (ko)
JP (1) JP3942670B2 (ko)
KR (1) KR100482499B1 (ko)
CN (1) CN1059436C (ko)
AR (1) AR023289A1 (ko)
AT (1) ATE197801T1 (ko)
AU (1) AU701271B2 (ko)
CA (1) CA2172354C (ko)
CZ (1) CZ289245B6 (ko)
DE (2) DE19510566A1 (ko)
DK (1) DK0733642T3 (ko)
DZ (1) DZ2003A1 (ko)
ES (1) ES2152444T3 (ko)
GR (1) GR3035410T3 (ko)
HU (1) HU226064B1 (ko)
IL (1) IL117265A (ko)
NO (1) NO305904B1 (ko)
NZ (1) NZ286224A (ko)
PL (1) PL184336B1 (ko)
PT (1) PT733642E (ko)
RU (1) RU2159768C2 (ko)
SK (1) SK281079B6 (ko)
UA (1) UA44712C2 (ko)
ZA (1) ZA961243B (ko)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100710547B1 (ko) * 2002-01-02 2007-04-24 에스케이 주식회사 (ｓ)-3-아미노-2,3,4,5-테트라히드로-2-옥소-1Ｈ-벤자제핀-1-아세트산 및 이의 에스테르 화합물의 제조방법
KR100710548B1 (ko) * 2002-12-26 2007-04-24 에스케이 주식회사 (ｓ)-3-아미노-2,3,4,5-테트라히드로-2-옥소-1Ｈ-1-벤자제핀-1-아세트산 및 이의 에스테르 화합물의 제조방법
KR101014545B1 (ko) * 2002-02-14 2011-02-16 애보트 헬스케어 프로덕츠 비.브이. 수-난용성 활성 물질의 경구용 고용체 제형

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
DE19750002A1 (de) * 1997-11-12 1999-05-20 Solvay Pharm Gmbh Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
FR2781483A1 (fr) * 1998-07-21 2000-01-28 Hoechst Marion Roussel Inc Derives de thioazepinone, procede de preparation et intermediaires de ce procede, application a titre de medicament et compositions pharmaceutiques les renfermant
DE19906310A1 (de) 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
US20020052370A1 (en) * 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
HUP0400988A3 (en) * 2001-05-18 2006-07-28 Solvay Pharm Gmbh Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments
WO2003022853A1 (en) * 2001-09-10 2003-03-20 Tibotec Pharmaceuticals Ltd. Method for the preparation of hexahydro-furo[2,3-b]furan-3-ol
BR0306701A (pt) 2002-01-16 2004-12-28 Solvay Pharm Bv Composto, sal do composto, sal de cálcio, método de preparação de um sal, composição farmacêutica, método de preparação de uma composição, e, uso de um sal
US6842358B2 (en) * 2002-08-01 2005-01-11 Netlogic Microsystems, Inc. Content addressable memory with cascaded array
US7045653B2 (en) * 2002-12-23 2006-05-16 Pfizer, Inc. Pharmaceuticals
US7262184B2 (en) 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7427611B2 (en) 2003-09-26 2008-09-23 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7452875B2 (en) 2003-09-26 2008-11-18 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
DE10344848A1 (de) * 2003-09-26 2005-04-14 Solvay Pharmaceuticals Gmbh Amidomethyl-substituierte l-(Carboxyalkyl)-cyclopentylcarbonylamino-benzazepin-N-essigsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enhaltende Arzneimittel
SA04250283B1 (ar) * 2003-09-26 2008-05-26 سولفاي فارماسيتيكالز جي أم بي أتش مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid
DE602004010172T2 (de) 2003-11-18 2008-09-11 Solvay Pharmaceuticals Gmbh Pharmazeutische zusammensetzungen zur behandlung von nierenfunktionsstörungen
US7232813B2 (en) * 2004-01-12 2007-06-19 Solvay Pharmaceuticals B.V. Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
DE602005009487D1 (de) * 2004-01-12 2008-10-16 Solvay Pharm Bv Neutrale endopeptidase (nep) und humane lösliche endopeptidase (hsep) hemmer für die prophylaxe und behandlung von neurodegenerativen erkrankungen
US20050267072A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
WO2006000564A1 (en) * 2004-06-23 2006-01-05 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
AU2005315608B2 (en) 2004-12-15 2011-03-31 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
TW200633713A (en) * 2004-12-23 2006-10-01 Solvay Pharm Bv Oral immediate release formulation of a poorly water-soluble active substance
US20060205625A1 (en) * 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
WO2007102171A2 (en) * 2006-03-07 2007-09-13 Panacea Biotec Ltd Novel salts of 1h-1-benzazepine-1-acetic acid, their preparation and pharmaceutical composition
US20070292503A1 (en) * 2006-06-16 2007-12-20 Gorissen Henricus R Oral pharmaceutical composition of poorly water-soluble active substance
US20070299054A1 (en) * 2006-06-22 2007-12-27 Rajesh Jain Oral pharmaceutical composition of a poorly water-soluble active agent
JP2011517313A (ja) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
AR079059A1 (es) 2009-12-07 2011-12-21 Abbott Healthcare Products Bv Acido ((3s)-3-(((1-(((2r)-2-carboxi-4-(1-naftil) butil) ciclopentil)-carbonil) amino )-2-oxo-2,3,4,5-tetrahidro-1h-1-benzazepin-1-il) acetico cristalino, su preparacion y uso
KR20180094131A (ko) 2010-09-01 2018-08-22 에자이 알앤드디 매니지먼트 가부시키가이샤 신장 손상을 갖는 개체에 대한 로카세린의 투여
KR101913442B1 (ko) 2010-09-01 2018-10-30 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
NZ611528A (en) 2010-12-15 2015-06-26 Theravance Biopharma R & D Ip Llc Neprilysin inhibitors
ME02295B (me) 2010-12-15 2016-02-20 Theravance Biopharma R&D Ip Llc Inhibitori neprilizina
ES2564275T3 (es) 2011-02-17 2016-03-21 Theravance Biopharma R&D Ip, Llc Derivados aminobutíricos sustituidos como inhibidores de neprilisina
ES2582640T3 (es) 2011-02-17 2016-09-14 Theravance Biopharma R&D Ip, Llc Derivados aminobutíricos sustituidos como inhibidores de neprilisina
EP2714660B1 (en) 2011-05-31 2018-09-26 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
WO2012166389A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
CN103596928B (zh) 2011-05-31 2017-02-15 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
JP6088047B2 (ja) 2012-05-31 2017-03-01 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 一酸化窒素ドナーであるネプリライシン阻害剤
JP6162229B2 (ja) 2012-06-08 2017-07-12 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
EP3199517B1 (en) 2012-06-08 2018-09-12 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
ES2615275T3 (es) 2012-08-08 2017-06-06 Theravance Biopharma R&D Ip, Llc Inhibidores de neprilisina
JP6549040B2 (ja) 2013-02-17 2019-07-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
CN105026374B (zh) 2013-03-05 2018-08-24 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
KR20160113291A (ko) 2014-01-30 2016-09-28 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 네프리리신 저해제
CN105960398A (zh) 2014-01-30 2016-09-21 施万生物制药研发Ip有限责任公司 5-联苯-4-杂芳基羰基氨基-戊酸衍生物作为脑啡肽酶抑制剂
DK3177627T3 (da) 2014-08-07 2019-10-21 Intra Cellular Therapies Inc Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-on-derivater med pde1-hæmmende aktivitet
KR102345318B1 (ko) 2014-12-02 2021-12-31 현대모비스 주식회사 에이밍 보정 구조를 구비한 차량용 램프
US9433598B2 (en) 2015-02-11 2016-09-06 Theravance Biopharma R&D Ip, Llc (2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid
PL3259255T3 (pl) 2015-02-19 2021-07-26 Theravance Biopharma R&D Ip, Llc Kwas (2R,4R)-5-(5'-chloro-2'-fluorobifenyl-4-ilo)-2-hydroksy-4-[(5-metylooksazolo-2-karbonylo)amino]pentanowy
CN105017154B (zh) * 2015-07-07 2017-10-10 浙江博聚新材料有限公司 一种3‑溴‑1,3,4,5‑四氢‑2h‑1‑苯并氮杂卓‑2‑酮制备方法
LT3408260T (lt) 2016-03-08 2021-07-26 Theravance Biopharma R&D Ip, Llc Kristalinė (2s,4r)-5-(5'-chlor-2-fluor-[1,1'-bifenil]-4-il)-2-(etoksimetil)-4-(3-hidroksi-izoksazol-5-karboksamido)-2-metilpentanoinė rūgštis ir jos panaudojimai
WO2017172795A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
PL424453A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)
EP3746081A4 (en) 2018-01-31 2021-10-27 Intra-Cellular Therapies, Inc. INNOVATIVE USES
PL424452A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
US20230118503A1 (en) * 2020-07-19 2023-04-20 Christopher Turski NEUTRAL ENDOPEPTIDASE (NEP) AND HUMAN SOLUBLE ENDOPEPTIDASE (hSEP) INHIBITORS FOR PROPHYLAXIS AND TREATMENT OF EYE DISEASES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608283A (ja) * 1983-06-29 1985-01-17 Mitsui Toatsu Chem Inc ベンゾチアゼピン誘導体およびその製造方法
US5457196A (en) * 1991-09-27 1995-10-10 Merrell Dow Pharmaceuticals Inc. 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
AU657793B2 (en) * 1991-09-27 1995-03-23 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
RU2124503C1 (ru) * 1992-05-18 1999-01-10 И.Р.Сквибб энд Санз, Инк. Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
IT1266570B1 (it) * 1993-07-30 1997-01-09 Zambon Spa Derivati della propanammide n-eteroaril sostituiti utili nel trattamento delle malattie cardiovascolari
IT1266571B1 (it) * 1993-07-30 1997-01-09 Zambon Spa Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100710547B1 (ko) * 2002-01-02 2007-04-24 에스케이 주식회사 (ｓ)-3-아미노-2,3,4,5-테트라히드로-2-옥소-1Ｈ-벤자제핀-1-아세트산 및 이의 에스테르 화합물의 제조방법
KR101014545B1 (ko) * 2002-02-14 2011-02-16 애보트 헬스케어 프로덕츠 비.브이. 수-난용성 활성 물질의 경구용 고용체 제형
KR100710548B1 (ko) * 2002-12-26 2007-04-24 에스케이 주식회사 (ｓ)-3-아미노-2,3,4,5-테트라히드로-2-옥소-1Ｈ-1-벤자제핀-1-아세트산 및 이의 에스테르 화합물의 제조방법

Also Published As

Publication number Publication date
NO961181D0 (no) 1996-03-22
HUP9600680A2 (en) 1997-01-28
DE59606160D1 (de) 2001-01-04
NZ286224A (en) 1997-09-22
ZA961243B (en) 1996-08-27
HUP9600680A3 (en) 1998-07-28
SK281079B6 (sk) 2000-11-07
EP0733642A1 (de) 1996-09-25
AU701271B2 (en) 1999-01-21
KR100482499B1 (ko) 2006-08-23
CZ289245B6 (cs) 2001-12-12
JPH08269011A (ja) 1996-10-15
NO961181L (no) 1996-09-24
HU9600680D0 (en) 1996-05-28
NO305904B1 (no) 1999-08-16
AR023289A1 (es) 2002-09-04
AU4821096A (en) 1996-10-03
DE19510566A1 (de) 1996-09-26
CA2172354A1 (en) 1996-09-24
DK0733642T3 (da) 2001-01-15
PT733642E (pt) 2001-03-30
CN1147506A (zh) 1997-04-16
ATE197801T1 (de) 2000-12-15
CZ86396A3 (en) 1996-10-16
ES2152444T3 (es) 2001-02-01
JP3942670B2 (ja) 2007-07-11
RU2159768C2 (ru) 2000-11-27
PL313433A1 (en) 1996-09-30
CA2172354C (en) 2002-10-08
DZ2003A1 (fr) 2002-07-20
IL117265A (en) 2000-07-16
PL184336B1 (pl) 2002-10-31
CN1059436C (zh) 2000-12-13
GR3035410T3 (en) 2001-05-31
US5677297A (en) 1997-10-14
EP0733642B1 (de) 2000-11-29
IL117265A0 (en) 1996-06-18
SK35496A3 (en) 1997-02-05
UA44712C2 (uk) 2002-03-15
HU226064B1 (en) 2008-04-28

Similar Documents

Publication Publication Date Title
KR960034178A (ko) 벤자제핀- 벤즈옥사제핀- 및 벤조티아제핀-n- 아세트산 유도체와 그 제조방법 및 그들을 함유한 약제학적 조성물
RU96105383A (ru) Производные бензазепин-, бензоксазепин- и бензотиазепин-n-уксусной кислоты, способ их получения и содержащие эти соединения лекарственные средства
KR960007545A (ko) 합성 흥분성 아미노산
ATE178067T1 (de) Camptothecinderivate
GR3037076T3 (en) Camptothecin derivatives
WO1990004918A3 (en) Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
OA08182A (fr) Nouveaux dérivés peptidiques à structure polycyclique azotée, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
EP1108427A3 (en) Compositions for and uses thereof for altering gene expression with phenylacetate and derivatives thereof
EP1437359A3 (en) Novel 3,6-Hemiketals from the Class of 9a-Azalides
WO2001026629A3 (en) Neutral-cationic lipid for nucleic acid and drug delivery
KR900016098A (ko) 카페인산의 유도체 및 이를 함유하는 약제학적 조성물
FI834702A0 (fi) Nya nitroalifatiska foereningar, deras framstaellningsfoerfarande och anvaendning
KR950017943A (ko) 아미디노페닐알라닌 유도체, 이의 제조방법, 이의 용도 및 이를 함유하는 항응고제로서의 조성물
KR890001965A (ko) 스퍼구알린 관련 유도체
KR910020004A (ko) 이소크로만 유도체
PT90125A (pt) Processo para a preparacao de derivados de benzopirano
HUP9802096A2 (hu) Piperidino-alkanol-vegyületeket tartalmazó orális adagolású oldat formájú gyógyszerkészítmény, és eljárás előállítására
AU5861586A (en) 3-aminopropyloxyphenyl derivatives their preparation and pharmaceutical compositions containing them
DK0470275T3 (da) Hudhvidgørende kosmetisk præparat
KR950032158A (ko) 신규의 티아진 또는 티오모폴린 유도체
BR0015122A (pt) Composição farmacêutica, e, método de tratamento de inflamação
KR920701144A (ko) 아미노산 유도체
KR970010756A (ko) 엔도테린 수용체 길항제
KR930007880A (ko) 비스(페닐)에탄 유도체
KR920700210A (ko) 신규 이미다졸 유도체, 그의 제법 및 그의 의약용도

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19960321

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20001229

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19960321

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20030529

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20040531

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20041230

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20050401

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20050401

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20080331

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20090331

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20100326

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20110324

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20120329

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20120329

Start annual number: 8

End annual number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Termination category: Default of registration fee

Termination date: 20140309